SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans

SARS-CoV-2 mRNA疫苗接种可在人体内引发强效且持久的滤泡辅助性T细胞反应。

阅读:8
作者:Philip A Mudd ,Anastasia A Minervina ,Mikhail V Pogorelyy ,Jackson S Turner ,Wooseob Kim ,Elizaveta Kalaidina ,Jan Petersen ,Aaron J Schmitz ,Tingting Lei ,Alem Haile ,Allison M Kirk ,Robert C Mettelman ,Jeremy Chase Crawford ,Thi H O Nguyen ,Louise C Rowntree ,Elisa Rosati ,Katherine A Richards ,Andrea J Sant ,Michael K Klebert ,Teresa Suessen ,William D Middleton ,Sharlene A Teefey ,Jane A O'Halloran ,Rachel M Presti ,Katherine Kedzierska ,Jamie Rossjohn ,Paul G Thomas ,Ali H Ellebedy

Abstract

SARS-CoV-2 mRNA vaccines induce robust anti-spike (S) antibody and CD4+ T cell responses. It is not yet clear whether vaccine-induced follicular helper CD4+ T (TFH) cell responses contribute to this outstanding immunogenicity. Using fine-needle aspiration of draining axillary lymph nodes from individuals who received the BNT162b2 mRNA vaccine, we evaluated the T cell receptor sequences and phenotype of lymph node TFH. Mining of the responding TFH T cell receptor repertoire revealed a strikingly immunodominant HLA-DPB1∗04-restricted response to S167-180 in individuals with this allele, which is among the most common HLA alleles in humans. Paired blood and lymph node specimens show that while circulating S-specific TFH cells peak one week after the second immunization, S-specific TFH persist at nearly constant frequencies for at least six months. Collectively, our results underscore the key role that robust TFH cell responses play in establishing long-term immunity by this efficacious human vaccine.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。